Search DIAN Data Resource Requests

Title:Addendum to “Comparing biomarkers between Down Syndrome, Autosomal Dominant, and Late onset Alzheimer Disease.”

Date of Request:06/26/2024

Status:approved

ID:DIAN-D2416

Aim 1:Question 1a: How does the severity of white matter hyperintensities compare between DS and ADAD?

Aim 2:How does the presence of microbleeds compare across DS and ADAD?

Aim 3:Is enlarged perivascular space a common finding across DS and ADAD?

Aim 4Are the presence and progression of WMH, microbleeds, and PVS due to inflammatory processes?

Title:Is Maternal or Paternal origin of ADAD mutations relevant for clinical or biomarker outcome?

Date of Request:06/14/2024

Status:approved

ID:DIAN-D2415

Aim 1:Our aim is to determine whether the onset of Alzheimer's disease (AD) is affected by the inheritance pattern (paternal versus maternal) of AD-causing mutations.

Title:Neuroinflammation Profiles in Alzheimer's Disease Patients with Distinct

Date of Request:06/03/2024

Status:approved

ID:DIAN-D2414

Aim 1:Overview the Landscape: Initially, we will assess the overall landscape of neuroinflammation across carriers of different risk variants.

Aim 2:Identify Unique Inflamed Cell Populations: We will then focus on identifying unique inflamed cell populations and compare the levels of inflammation across different risk variant carriers.

Aim 3:Evaluate Common Modulatory Factors: Finally, we will evaluate whether common factors can modulate neuroinflammation in various AD patients, potentially identifying targets for therapeutic intervention.

Title:Autosomal Dominant Alzheimer's Disease

Date of Request:05/26/2024

Status:pending

ID:DIAN-D2413

Aim 1:Investigate longitudinal patterns of clinical decline and neuroimaging changes in Autosomal Dominant Alzheimer's Disease.

Title:Amyloid Chronicity in Autosomal Dominant Alzheimer’s Disease

Date of Request:05/23/2024

Status:approved

ID:DIAN-D2412

Aim 1:Examine associations between estimation of amyloid chronicity and Estimated Year of Symptom Onset (EYO) in Autosomal Dominant Alzheimer Disease

Aim 2:Compare longitudinal rate of amyloid accumulation across autosomal dominant Alzheimer Disease, sporadic Alzheimer Disease, and Down Syndrome

Aim 3:Determine the average length of time between becoming amyloid positive and cognitively impaired in different forms of Alzheimer Disease (autosomal dominant Alzheimer Disease, sporadic Alzheimer Disease, and Down Syndrome)

Title:Sample size estimates for biomarkers in prevention trials

Date of Request:04/17/2024

Status:approved

ID:DIAN-D2411

Aim 1:Assess the rate and variance of serial imaging measures in the Dominantly Inherited Alzheimer Network (DIAN) study

Aim 2:Compare sample size estimates from imaging outcomes with biofluid and cognitive measures

Aim 3:Assess the different power and design requirements for studies using different potential trial inclusion criteria (including but not limited to estimated years to onset, amyloid and tau positivity, cogntiive status) and suitable target treatment effects (reduced rate of atrophy/cognitive decline or reduction of absolute levels of AD-related pathology by end of study)

Aim 4Assess and compare the requirements for classical parallel arm trial design with more novel approaches (run-in designs, common close, staggered starts)

Title:Influence of tau on neurodegeneration in ADAD

Date of Request:04/04/2024

Status:approved

ID:DIAN-D2410

Aim 1:Our overall objective is to compare the cross-sectional and longitudinal trajectories of CSF Tau (including pTau181, NT1, pTau205, pTau217, MTBR-tau) and regional Tau-PET with the neurodegenerative trajectories using of CSF NfL and grey-matter volumes in pathogenic variant carriers in DIAN.

Title:Development of retinal biomarkers in autosomal dominant Alzheimer’s disease: A pilot study

Date of Request:03/29/2024

Status:approved

ID:DIAN-D2409

Aim 1:Identify retinal biomarker differences between ADAD mutation carriers and non-carriers. H1: ADAD mutation carriers will have a higher number and surface area of retinal Ab deposits (retinal inclusion bodies) than non-carriers, as shown by FAF imaging. H2: ADAD mutation carriers will have volume and thickness differences in the mRNFL and GC-IPL relative to non-carriers, as measured using SD-OCT imaging.

Aim 2:Project aim 2: Determine whether retinal biomarker alterations predict cerebral biomarker status in ADAD. H3: Number and surface area of retinal inclusion bodies will be able to predict cerebral Ab accumulation (measured via PET and/or CSF as part of the DIAN-Obs protocol) in ADAD.

Title:“Correlating between Sporadic and Autosomal Dominant Alzheimer's Disease: Longitudinal Analysis of Clinical and Neuroimaging Dynamics with a Focus on Sporadic GAP-43 Measurements”

Date of Request:03/28/2024

Status:pending approval

ID:DIAN-D2408

Aim 1:1. Investigate longitudinal patterns of clinical decline and neuroimaging changes in both sporadic and Autosomal Dominant Alzheimer's Disease (ADAD).

Aim 2:2. Specifically, explore the correlation between clinical parameters, and neuroimaging measures to shed light on potential shared mechanisms and differences between sporadic and ADAD considering GAP-43 measurements.

Title:Simulation of AD progression enabled by multivariate data anlysis

Date of Request:03/26/2024

Status:pending approval

ID:DIAN-D2407

Aim 1:To determine the AD trajectory in relation to mutisite mutivariate variables.